drugset / Trial / NCT01564914
A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma
Phase 2
Completed
22 enrolled
Tracon Pharmaceuticals Inc.
Case Comprehensive Cancer Center · collabThe Cleveland Clinic · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of TRC105 in patients with recurrent or progressive glioblastoma after prior antiangiogenic therapy (including anti-VEGF therapy)
Timeline
- Start
- 2012-05
- Primary completion
- 2015-06
- Completion
- 2015-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carotuximab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Background | Bevacizumab | Monoclonal antibody | 10 mg/kg | — |